Jae Yong Cho

Dr. Jae Yong Cho


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The Lancet
Verified
Journal Article
Closed access
YKYoon-Koo Kang
Yoon-Koo Kang
NBNarikazu Boku
Narikazu Boku
TSTaroh Satoh
Taroh Satoh
MRMin-Hee Ryu
Min-Hee Ryu
YCYee Chao
Yee Chao
LCLi-Tzong Chen
Li-Tzong Chen

1 January 2014 in The Lancet
Verified
Journal Article
Closed access
CFCharles S Fuchs
Charles S Fuchs
JTJiri Tomasek
Jiri Tomasek
JCJae Yong Cho
Jae Yong Cho
FDFilip Dumitru
Filip Dumitru
RPRodolfo Passalacqua
Rodolfo Passalacqua
Josep TaberneroJosep Tabernero
Josep Tabernero

1 January 2012 in The Lancet
Verified
Journal Article
Closed access
Yung-Jue BangYung-Jue Bang
Yung-Jue Bang
YKYoung-Woo Kim
Young-Woo Kim
HYHan-Kwang Yang
Han-Kwang Yang
HCHyun Cheol Chung
Hyun Cheol Chung
YPYoung-Kyu Park
Young-Kyu Park
SNSung Hoon Noh
Sung Hoon Noh

1 August 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BSBo Hwa Sohn
Bo Hwa Sohn
JHJun-Eul Hwang
Jun-Eul Hwang
HJHee-Jin Jang
Hee-Jin Jang
HLHyun-Sung Lee
Hyun-Sung Lee
SOSang Cheul Oh
Sang Cheul Oh
JLJu-Seog Lee
Ju-Seog Lee
Purpose: The Cancer Genome Atlas (TCGA) project recently uncovered four molecular subtypes of gastric cancer: Epstein–Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS), and chromosomal instability (CIN). However, their clinical significances are currently unknown. We aimed to investigate the relationship between subtypes and prognosis of patients with gastric cancer. Experimental Design: Gene expression data from a TCGA cohort (n = 262) were used to develop a subtype prediction model, and the association of each subtype with survival and benefit from adjuvant chemotherapy was tested in 2 other cohorts (n = 267 and 432). An integrated risk assessment model (TCGA risk score) was also developed. Results: EBV subtype was associated with the best prognosis, and GS subtype was associated with the worst prognosis. Patients with MSI and CIN subtypes had poorer overall survival than those with EBV subtype but better overall survival than those with GS subtype (P = 0.004 and 0.03 in two cohorts, respectively). In multivariate Cox regression analyses, TCGA risk score was an independent prognostic factor [HR, 1.5; 95% confidence interval (CI), 1.2–1.9; P = 0.001]. Patients with the CIN subtype experienced the greatest benefit from adjuvant chemotherapy (HR, 0.39; 95% CI, 0.16–0.94; P = 0.03) and those with the GS subtype had the least benefit from adjuvant chemotherapy (HR, 0.83; 95% CI, 0.36–1.89; P = 0.65). Conclusions: Our prediction model successfully stratified patients by survival and adjuvant chemotherapy outcomes. Further development of the prediction model is warranted. Clin Cancer Res; 23(15); 4441–9. ©2017 AACR.

3 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
SOSang Cheul Oh
Sang Cheul Oh
BSBo Hwa Sohn
Bo Hwa Sohn
JCJae-Ho Cheong
Jae-Ho Cheong
SKSang-Bae Kim
Sang-Bae Kim
JLJae Eun Lee
Jae Eun Lee
JLJu-Seog Lee
Ju-Seog Lee
Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict. Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype (MP) and epithelial phenotype (EP), by analyzing genomic and proteomic data. Molecularly, MP subtype tumors show high genomic integrity characterized by low mutation rates and microsatellite stability, whereas EP subtype tumors show low genomic integrity. Clinically, the MP subtype is associated with markedly poor survival and resistance to standard chemotherapy, whereas the EP subtype is associated with better survival rates and sensitivity to chemotherapy. Integrative analysis shows that signaling pathways driving epithelial-to-mesenchymal transition and insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) pathway are highly activated in MP subtype tumors. Importantly, MP subtype cancer cells are more sensitive to inhibition of IGF1/IGF1R pathway than EP subtype. Detailed characterization of these two subtypes could identify novel therapeutic targets and useful biomarkers for prognosis and therapy response.

31 March 2011 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JCJae Yong Cho
Jae Yong Cho
JLJae Yun Lim
Jae Yun Lim
JCJae-Ho Cheong
Jae-Ho Cheong
YPYun-Yong Park
Yun-Yong Park
SYSe-Lyun Yoon
Se-Lyun Yoon
JLJu-Seog Lee
Ju-Seog Lee
Purpose: Despite continual efforts to develop a prognostic model of gastric cancer by using clinical and pathologic parameters, a clinical test that can discriminate patients with good outcomes from those with poor outcomes after gastric cancer surgery has not been established. We aim to develop practical biomarker-based risk score that can predict relapse of gastric cancer after surgical treatment. Experimental Design: Microarray technologies were used to generate and analyze gene expression profiling data from 65 gastric cancer patients to identify biomarker genes associated with relapse. The association of expression patterns of identified genes with relapse and overall survival was validated in independent gastric cancer patients. Results: We uncovered two subgroups of gastric cancer that were strongly associated with the prognosis. For the easy translation of our findings into practice, we developed a scoring system based on the expression of six genes that predicted the likelihood of relapse after curative resection. In multivariate analysis, the risk score was an independent predictor of relapse in a cohort of 96 patients. We were able to validate the robustness of the six-gene signature in an additional independent cohort. Conclusions: The risk score derived from the six-gene set successfully prognosticated the relapse of gastric cancer patients after gastrectomy. Clin Cancer Res; 17(7); 1850–7. ©2011 AACR.